.

  FOR IMMEDIATE RELEASE
Contact:  

Robert F. Apple, Chief Operating Officer
InKine Pharmaceutical Company, Inc.
215-283-6850

Donald C. Weinberger
Wolfe Axelrod Weinberger Assoc. LLC
212-370-4500, 212-370-4505 fax
[email protected]


INKINE INITIATES DOSING OF SUBJECTS IN LAXATIVE STUDY OF VISICOL TABLETS

 

BLUE BELL, PA March 13, 2003 - InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that the first 10 patients began treatment yesterday in the Company's post-marketing study of the use of Visicol tablets (sodium phosphate) as a laxative. Visicol tablets are currently marketed in the US for cleansing of the bowel prior to colonoscopy in adults. The study, which is being performed in adult, healthy volunteers, is a randomized, open label trial that will investigate the safety and laxative effects of two low dose regimens of Visicol tablets compared to Miralax®, a marketed prescription laxative. Subjects will be treated for one week and study results are expected in the second quarter of 2003. The constipation marketplace represents a potentially large extension of Visicol's utility, with over two million patients seeking treatment each year yielding over 3.5 million prescriptions.

"Sodium phosphate solution and other marketed colon cleansing products are used as laxatives at lower doses," said Martin Rose, M.D., J.D., InKine's Executive Vice President for Research and Development. "It is highly likely that Visicol will also prove to be an effective laxative. This study will give us information on the safety of two low doses of Visicol tablets given daily for one week. In addition, we will be focusing on the dose response and the time course of laxative effects with Visicol. The comparison with Miralax will be important, because the labeling for Miralax indicates that it may take two to four days to produce a bowel movement."

About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's first product, Visicol® is the first and only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IBStat®, is a novel oral hysocyamine spray for the treatment of Irritable Bowel Syndrome (IBS) and spasm of the colon. Additionally, the Company has other development programs such as Colirest™, which is in clinical trials for the treatment of Crohn's disease and completed Phase II trials for the treatment of ulcerative colitis. For further information, please visit InKine on their web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.